Clinical Trial Update: Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects [Phase 1]

View source ↗

Summary

This Phase 1 dose-escalation study of Valortim (MDX-1303) administered intravenously in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• Valortim (MDX-1303)

Snippet

Sponsor: PharmAthene, Inc. | Conditions: Anthrax | Phase 1 | Status: COMPLETED